Chemed Corporation: Building Wealth in Unglamorous Industries
Empire of Care
<pChemed Corporation is an $8.5 billion holding company that owns a plumbing service famous for clearing clogged drains and a hospice provider that manages the final days of terminal illness. These are not, by any conventional measure, growth businesses. Plumbing is a trade as old as indoor sewage; hospice is a Medicare reimbursement game played on regulatory spreadsheets. Yet since 2003, Chemed has compounded earnings per share at 21 percent annually, a rate that humiliates most technology enterprises and defies the physical laws of service economics. The company has achieved this not by disrupting incumbents or capturing massive market share, a href=”https://www.rotorooter.com” target=”_blank” rel=”noopener noreferrer”>Roto-Rooter holds only 2 to 3 percent of the fragmented plumbing market, and VITAS controls just 12 percent of hospice, ut by treating its operations as cash-generating assets to be optimized and its own stock as the most attractive investment opportunity available. Chemed is a capital-allocation machine that happens to drain pipes and administer morphine. The question facing anyone studying the business today is whether the machine can survive its own success: a post-pandemic normalization that may have permanently altered demand, a government payer increasingly squeezed by demographic math, and a leadership transition that threatens to replace financial discipline with operational ambition.The Arithmetic of Aversion
The defining feature of Chemed is not what it owns but how it refuses to own. Since 2004, the company has generated $3.7 billion in free cash flow. Of that sum, it deployed $700 million on acquisitions, $300 million on dividends, and $2.5 billion on share repurchases. The result is a share count that has collapsed from 25 million to 15 million, a 40 percent reduction that has transformed modest operational growth into extraordinary shareholder returns. This is not a company that reinvests for empire; it is a company that harvests.
The operating units themselves are deliberately constrained. Roto-Rooter grows revenue at roughly 6 percent annually; VITAS grows at the same pace. Both convert that top-line growth into roughly 12 percent earnings growth through margin expansion. This is the base layer. The compounding occurs at the corporate level, where management treats the stock as a perpetual acquisition target, buying back shares with the urgency of a strategic acquirer closing a synergistic deal. The holding company maintains a net cash position, ot because it fears leverage, but because it refuses to overpay for growth. When opportunities to buy franchises or small hospice operators arise at reasonable prices, Chemed acts; when prices inflate, it simply buys itself.
This approach requires a specific and rare corporate psychology: operational agnosticism. Chemed’s management does not view Roto-Rooter as a “plumbing platform” or VITAS as a “healthcare mission.” They view both as sources of free cash flow per share. If either business could be sold at a price that allows superior redeployment of capital, the model demands an exit. This is not theoretical. In the 1990s, Roto-Rooter attempted to roll up HVAC services and failed, a scar that still shapes corporate memory. The lesson learned was not to try harder at integration, but to avoid owning businesses where scale does not translate to returns. The holding company structure exists precisely to preserve this freedom, to remain, as one might put it, promiscuous about assets but monogamous about metrics.
Regulatory Geography as Strategy
The most underappreciated competitive advantage in Chemed’s portfolio is not brand recognition or operational efficiency, but the deliberate geographic selectivity of VITAS. The hospice industry is fragmented and regulated at the state level, creating a patchwork of competitive intensity. VITAS has chosen to operate almost exclusively in high-regulation, high-population states. Florida, for example, licenses only fifty hospice operators statewide; Los Angeles County alone contains 1,900. This is not an accident of history but a strategic moat constructed through exclusion.
By concentrating in states where regulatory barriers limit entry, VITAS achieves asset utilization rates that competitors cannot match. While the bottom half of the hospice industry struggles with 6 to 9 percent EBITDA margins, VITAS generates 15 to 22 percent. The difference is not operational wizardry but market selection. In dense, regulated markets, VITAS can maintain higher census counts per facility and negotiate better staffing ratios. In fragmented, lightly regulated markets, hospice becomes a commodity service where small operators compete on price and religious affiliation.
This strategy is durable because it relies on political friction. State licensing boards do not dissolve overnight, and the capital required to build hospice infrastructure in high-barrier states acts as a deterrent to new entrants. However, the strategy is also geographically constrained. VITAS cannot easily expand into rural or low-regulation states without accepting the margin compression that defines those markets. The company has essentially partitioned the map, claiming only the territory where the economics work. This creates a finite universe of addressable markets. If VITAS saturates the high-regulation, high-population zones, growth must either slow or accept lower returns. The 12 percent earnings growth assumption depends on the continued existence of virgin territory within this specific regulatory geography: dependency that becomes more precarious as the company grows.
The Premium for Panic
Roto-Rooter operates under a different but complementary logic. The company controls roughly 15 percent of the drain-cleaning market, but more importantly, 70 to 75 percent of its revenue derives from emergency, same-day service. When a basement floods at midnight, the homeowner does not comparison-shop. They call the brand they remember from childhood television commercials and pay the premium for immediate arrival. This is pricing power born of biological urgency, not technological superiority.
The emergency service model creates acyclical revenue streams and high conversion rates. Unlike scheduled maintenance or renovation plumbing, emergency work is non-discretionary and price-inelastic. Roto-Rooter’s brand, cultivated over ninety years, functions as a form of insurance against the anxiety of household disaster. Competitors, whether mom-and-pop operators or private equity roll-ups, struggle to replicate the national marketing scale and the local response-time infrastructure that supports this premium.
Yet this advantage is currently undergoing stress tests. The COVID-19 pandemic created a massive demand pull-forward. Stuck at home, Americans noticed leaking fixtures and deteriorating pipes; government stimulus provided the liquidity to fix them. Since the first quarter of 2023, Roto-Rooter has faced negative comparable sales as this demand normalizes. Management admits they cannot determine whether the current weakness represents a cyclical retrenchment or a structural step-down to a lower baseline of demand. If the pandemic accelerated household maintenance into 2020-2021 that would have otherwise occurred over five years, the “normalized” growth rate may be closer to 2 or 3 percent than the historical 6 percent. In that scenario, the 21 percent EPS CAGR becomes mathematically impossible to sustain through buybacks alone, forcing either aggressive price increases in a potentially softer demand environment or acceptance of lower growth.
When the Payer Changes the Price
VITAS faces a parallel uncertainty regarding its economic baseline. The demographic tailwind is undeniable: American deaths will rise from roughly 3 million annually to 4.5 million by the 2030s as the Baby Boom generation ages. Hospice penetration rates have stabilized around 50 percent of deaths, suggesting volume growth is structurally assured. However, VITAS has no pricing power. Ninety-three percent of revenue comes from Medicare, and the government currently pays for 30 percent of all Medicare expenses incurred in a patient’s final year of life. As budget pressures mount, hospice reimbursement represents an obvious target for cost containment.
The VITAS margin structure depends on a delicate equilibrium: volume growth offsets reimbursement stability. If Medicare freezes or cuts rates in real terms while volumes rise, the business faces a squeeze. Unlike a pharmaceutical company with patent protection or a hospital system with regional monopoly, VITAS cannot pass cost inflation through to its payer. Labor costs for hospice nurses and aides rise with market wages; reimbursement rates rise with Congressional appropriations. If the latter lags the former, the 15 to 22 percent EBITDA margins compress toward the industry average.
This risk is exacerbated by the geographic constraints mentioned earlier. If VITAS exhausts the high-margin markets of Florida and similar states, it faces a choice: expand into low-regulation, low-density markets where margins are thin, or slow growth. Either option breaks the 12 percent earnings growth model. The company is effectively long on death and short on Medicare solvency: position that has worked for two decades but assumes the government will continue subsidizing end-of-life care at current intensity levels even as the eligible population balloons by 50 percent.
The Operator’s Dilemma
Chemed’s corporate model depends on a leadership culture that prioritizes free cash flow per share above all operational metrics. This culture is embodied in Kevin McNamara, the 70-year-old CEO who has guided the company since the 1980s. McNamara is not an operator in the conventional sense; he is a capital allocator who happens to oversee plumbing trucks and hospice beds. His presumed successor is Nicholas Westfall, who has run VITAS since 2009. Westfall is by training and experience an operator: man who has built market share in a specific healthcare vertical.
This transition represents an existential risk to the Chemed model. If Westfall or any subsequent CEO shifts priority from capital allocation to operational growth, if they view VITAS as a healthcare platform to be expanded rather than a cash cow to be milked, the discipline of the buyback program falters. The temptation will be strong. Healthcare executives are trained to pursue market share, clinical outcomes, and scale. Plumbing executives are trained to roll up competitors and bundle services. Neither instinct serves the shareholder when the alternative is retiring 5 percent of the float annually at attractive prices.
The corporate advantage of Chemed is not operational excellence but the willingness to shrink. This is an unnatural act for most executives, who measure themselves by headcount growth, revenue milestones, and empire-building. McNamara’s departure will test whether the board can install a CEO who views the job as portfolio management rather than business expansion. If the new leadership attempts to transform Roto-Rooter into a full-service home services platform or VITAS into a comprehensive palliative care network, the capital-allocation engine seizes.
Defending the Fragmented
Roto-Rooter currently faces its most aggressive competitive threat in years. Private equity firms have consolidated plumbing and HVAC assets into roll-ups like Apex and Ben Franklin, attempting to create multi-service home maintenance platforms that can achieve marketing efficiency through bundling. These competitors have actively poached Roto-Rooter’s general managers, 20 percent departed in 2021, presumably to capture institutional knowledge and customer relationships.
Roto-Rooter’s response has been defensive rather than offensive. The company has focused on rehiring departed managers (half returned within two years) and emphasizing its historical brand equity rather than attempting to match the PE roll-ups service-for-service. This is prudent given the company’s failed HVAC expansion in the 1990s, but it also acknowledges a strategic limitation. Roto-Rooter cannot compete with bundled service offerings without sacrificing the emergency-service focus that generates its margins. If a homeowner calls for HVAC maintenance and the technician also clears drains, that represents a convenience; if Roto-Rooter adds HVAC technicians to its fleet to compete, it dilutes the emergency response infrastructure and risks becoming a generalist contractor with average margins.
The fragmentation of the plumbing market protects Roto-Rooter to some degree, o single competitor can achieve national scale quickly enough to threaten its brand recognition overnight. However, if private equity succeeds in creating regional oligopolies that control local Google search results and customer acquisition channels, Roto-Rooter’s 2 to 3 percent market share becomes vulnerable to slow erosion. The business does not require massive market share to succeed, but it does require pricing power. If competitors bundle drain cleaning as a loss leader to sell HVAC replacements, the emergency premium could compress.
The Limits of Shrinking
Chemed’s 21 percent EPS CAGR is a mathematical artifact of combining 12 percent earnings growth with a share count that declines 2 to 3 percent annually. This is a beautiful machine while it lasts, but machines require maintenance. The company has reduced shares outstanding by 40 percent since 2004; it cannot repeat this trick indefinitely without eventually taking the company private. At some point, the denominator becomes too small to provide the compounding kick, and the business must rely solely on operational growth.
If Roto-Rooter’s post-COVID normalization proves structural rather than cyclical, if the “new normal” is 3 percent revenue growth rather than 6 percent, and if VITAS faces Medicare reimbursement pressure or geographic saturation, the operational engine produces less cash. The buyback program then becomes a game of diminishing returns, retiring fewer shares with the same dollars as the stock price rises. The model does not break immediately, but the 21 percent CAGR drifts toward the mid-teens, then the low teens.
Chemed has created an empire of care by refusing to care too much about empire. It treats Roto-Rooter’s plumbing trucks and VITAS’s hospice beds as interchangeable sources of cash, deploying that cash with ruthless efficiency toward the reduction of shares. This approach has generated returns that defy the mundane nature of the underlying services. But the model rests on three fragile assumptions: that Medicare will continue to fund hospice generously as deaths multiply; that Roto-Rooter’s emergency pricing power remains insulated from bundled competition; and that the next CEO will possess the same aversion to operational empire-building that characterized the last. The plumbing is sound, the medicine is compassionate, but the economics are contingent on a discipline that history suggests is harder to inherit than to create.
The franchise architecture of Roto-Rooter reveals the precision with which Chemed calibrates ownership. Of the 360 operating units, roughly two-thirds are company-owned branches generating the bulk of EBITDA, while the remaining third consists of independent franchisees and contractors who pay annual fees totaling approximately $7 million. These fees arrive at near-perfect margins, there is virtually no incremental cost to licensing the brand, but they represent only 6 percent of segment earnings. The economics illuminate Chemed’s preference for capital-light revenue where possible, but capital-controlled operations where necessary.
The distinction matters because the franchisees represent both a competitive shield and a strategic limitation. Between 2018 and 2019, Chemed spent approximately $200 million repurchasing franchises from operators who wished to exit, converting them to company-owned branches where margins are higher and capital allocation is direct. Yet since that surge, annual acquisition spending has fallen below $10 million. The easy targets, the franchisees in desirable markets willing to sell at reasonable multiples, have largely been exhausted. The remaining 360 franchisees presumably operate in territories where either the economics do not justify corporate ownership or the operators are not motivated sellers. This creates a natural ceiling on the branch conversion strategy. Chemed cannot roll up its own franchise network indefinitely; it has already picked the low-hanging fruit, and the tree is not growing new branches.
The hybrid model also creates a vulnerability that pure company-owned operations would avoid. When private equity competitors targeted Roto-Rooter’s general managers in 2021, they were not merely hiring technicians; they were acquiring the operational knowledge of how to run emergency-service plumbing at scale. The fact that half of these poached managers returned within eighteen months suggests that the grass was not greener at Apex or Ben Franklin, but the incident exposed the fragility of the human infrastructure. Plumbing is not a business of proprietary algorithms; it is a business of truck rolls, dispatch logistics, and customer service protocols that can be reverse-engineered by anyone with sufficient capital and patience. The brand protects Roto-Rooter in the consumer’s mind, but the operational know-how walks out the door every evening.
The Certificate of Need and the Empty Map
To understand why VITAS cannot simply replicate its Florida model in new territories, one must examine the specific regulatory mechanisms that create its moat. In high-barrier states, hospice providers operate under Certificate of Need (CON) laws or stringent licensing caps that limit the number of operators by service area. Florida’s fifty-operator ceiling is not arbitrary; it reflects a deliberate policy to prevent overcapacity in a service where fixed costs are high and empty beds represent wasted resources. These regulations function as a cartel manager, limiting supply to match projected demand and ensuring that incumbents maintain utilization rates sufficient to cover overhead.
The geographic selectivity this enables is stark. In Los Angeles County, where regulations are fragmented and enforcement is diffuse, 1,900 hospices compete for patients, driving margins down to the single digits. In VITAS’s core markets, the limited license count allows the company to maintain higher census counts per facility, spreading administrative costs across more patient-days and achieving the 15 to 22 percent EBITDA margins that subsidize the corporate buyback program. This is not operational leverage in the traditional sense; it is regulatory leverage, derived from the political difficulty of obtaining new licenses in saturated markets.
The problem is that the map of high-regulation, high-population states is finite and increasingly colored in. VITAS has spent decades identifying and entering the Floridas of the world while avoiding the rural counties of Montana or the deregulated exurbs of Texas. As the company grows, the remaining white space consists increasingly of markets that fail one or both criteria: either the population density is too low to support efficient asset utilization, or the regulatory barriers are too porous to prevent price competition.
When VITAS exhausts the suitable markets, and the slowing pace of new facility openings suggests this point is approaching, the business faces a binary choice. It can expand into low-regulation territories, accepting the margin compression that comes with competing against 1,900 local operators, or it can stagnate, becoming a cash cow that no longer grows earnings at 12 percent annually. Neither option supports the corporate EPS growth model. The first destroys the margin structure; the second removes the earnings growth that buybacks amplify. The regulatory moat, in other words, becomes a cage once the suitable territory is fully cultivated.
The Medicare Mathematics
The reimbursement risk facing VITAS is not merely a matter of Congressional mood or fiscal austerity. The Medicare hospice benefit operates under a specific fiscal architecture that creates inherent tension between volume and value. The government pays a per diem rate, approximately $200 per day for routine home care, higher for inpatient crises, regardless of the patient’s actual resource consumption. This rate is adjusted annually by a market basket update tied to medical inflation, but the adjustment frequently lags actual cost inflation, particularly in labor-intensive services like hospice nursing.
More critically, the hospice benefit includes an aggregate cap mechanism. If a provider’s total Medicare reimbursement exceeds a statutory cap based on the number of beneficiaries served, the provider must repay the excess. This cap creates a natural brake on margin expansion: as VITAS grows volume by serving more patients, it approaches the cap threshold where incremental revenue becomes subject to clawback. The company has managed this constraint historically by optimizing length of stay, hospice is most profitable in the middle weeks of enrollment, when per-patient costs are lowest, but as the government scrutinizes long-stay hospice patients for potential fraud or inappropriate admission, this optimization becomes legally perilous.
The demographic tailwind of 4.5 million annual deaths by the 2030s thus presents a paradox. More deaths mean more potential hospice patients, but if Medicare faces fiscal stress from this same demographic bulge, the per diem rates may stagnate or decline in real terms. The government already pays for 30 percent of all Medicare spending in the final year of life; as the Baby Boom generation enters this phase, that percentage represents an unsustainable trajectory. Congress has few options to control Medicare costs: it can reduce benefits, increase eligibility ages, or cut provider reimbursement. Hospice reimbursement is politically softer than hospital or physician payments because the patients are by definition terminal and the providers are corporations rather than beloved local doctors.
If reimbursement rates decline by even 10 percent, a plausible scenario under aggressive deficit reduction, VITAS’s margins compress toward the industry mean. The business does not collapse; hospice will always be necessary. But the 15 to 22 percent EBITDA margins become 10 to 15 percent margins, and the 12 percent earnings growth becomes 3 to 5 percent growth. At the corporate level, this transforms Chemed from a compounding machine into a mature utility, forced to choose between accepting lower growth or making riskier acquisitions to replace the lost earnings power.
The Succession Scenario
The transition from Kevin McNamara to Nicholas Westfall, or to an external candidate, represents more than a change in personnel. It represents a test of whether a corporate culture can be transmitted across generations when that culture is defined by restraint rather than ambition. McNamara’s tenure has been marked by a consistent refusal to overpay for growth. When Roto-Rooter’s HVAC expansion failed in the 1990s, he did not attempt a turnaround; he exited. When franchise prices rose in recent years, he stopped buying. This discipline requires viewing one’s own businesses with the cold eye of a portfolio manager rather than the protective pride of a founder.
Westfall, should he ascend, will bring a different biography. As the head of VITAS since 2009, he has built market share in hospice, navigated regulatory complexity, and managed clinical operations. These are operational virtues, but they are not capital-allocation virtues. The temptation facing any operator-turned-CEO is to view the corporate treasury as a tool for strategic expansion rather than financial engineering. Westfall might look at Roto-Rooter’s stagnating growth and see an opportunity to acquire HVAC capabilities that Chemed lacked in the 1990s, reasoning that modern integration tools and private equity competition demand a response. He might look at VITAS’s regulatory constraints and see a mandate to lobby for deregulation or vertical integration into palliative care, reasoning that the company should control the entire end-of-life continuum.
Any of these strategies would be reasonable for a normal CEO. They would be fatal to the Chemed model. The 21 percent EPS CAGR depends on treating free cash flow as a resource to be returned to shareholders, not reinvested in operational expansion. If Westfall deploys capital to transform Roto-Rooter into a comprehensive home services platform, or if he directs VITAS to acquire struggling hospices in low-margin markets to maintain volume growth, the buyback program diminishes. The share count stops shrinking. The mathematical alchemy of converting 6 percent revenue growth into 21 percent earnings growth ceases.
The board’s role here is crucial and uncertain. Chemed’s directors have presided over two decades of buybacks; they understand the model intellectually. But boards tend to defer to operating CEOs who promise growth and market relevance. If Westfall argues that Roto-Rooter must defend its turf against Apex through acquisition, or that VITAS must achieve national scale to negotiate with Medicare Advantage plans, the board may authorize a deviation from the pure capital-allocation script. Once broken, this discipline is difficult to restore. Share buybacks are politically easier when the stock is cheap; they become controversial when the price has risen and operational investments appear to offer higher immediate returns.
The Private Market Floor
There is a hidden constraint on Chemed’s buyback program that receives insufficient attention: the private market value of the operating subsidiaries. As the company retires shares, the remaining equity becomes increasingly concentrated in the hands of long-term holders who understand the model. At some point, perhaps when the share count falls below 10 million, the stock’s liquidity deteriorates and the valuation disconnects from the private market value of Roto-Rooter and VITAS as standalone assets.
If Chemed continues shrinking the float while the businesses generate stable cash, the equity becomes a quasi-private entity with public reporting requirements but no public float. This creates an arbitrage opportunity for private equity firms. A buyout firm could acquire Chemed, separate Roto-Rooter and VITAS, and sell them individually for more than the combined enterprise value, particularly if the hospice roll-up market remains frothy. The buyback program, in other words, contains the seeds of its own termination. By making the company smaller and more cash-rich, Chemed makes itself an increasingly attractive LBO target.
McNamara has presumably considered this dynamic. The net cash balance sheet, unusual for a company of this size, serves as a partial defense against acquisition, as does the dual-class or controlled structure if one exists. But if the share count continues to fall while earnings stagnate due to operational headwinds, the math becomes undeniable. At 15 million shares and an $8.5 billion market cap, Chemed trades at roughly $566 per share. If the company continues retiring 5 percent of shares annually, in five years the count falls to approximately 11.7 million shares. If the market cap remains constant, the price rises to $726 per share; if the multiple contracts due to growth concerns, the price stagnates but the yield becomes increasingly attractive to financial buyers.
The capital-allocation model thus faces a horizon. It cannot continue indefinitely because the company cannot buy back 100 percent of its shares while remaining public. The endpoint is either a take-private transaction, a strategic sale of one or both divisions, or a cessation of buybacks in favor of a massive special dividend. The current management prefers buybacks because they are tax-efficient and reversible. But the finite nature of the strategy means that the 21 percent historical CAGR is not a perpetual expectation but a historical artifact of a specific period in the company’s capital structure.
The Fragmentation Paradox
Both Roto-Rooter and VITAS operate in fragmented markets that should, in theory, allow indefinite market share gains. Roto-Rooter has 2 to 3 percent of plumbing; VITAS has 12 percent of hospice. The strategic logic of rolling up mom-and-pop competitors to achieve scale efficiencies is compelling on paper. Yet Chemed has largely abandoned aggressive roll-ups in both divisions, not because opportunities do not exist, but because the economics of fragmentation are more subtle than the private equity playbook assumes.
In plumbing, the fragmentation persists because the business is fundamentally local and emergency-driven. A national brand cannot leverage scale to reduce the cost of a truck roll in Cincinnati; the truck, the technician, and the dispatch center must exist locally regardless of corporate ownership. The mom-and-pop operator with one truck and no corporate overhead can often clear drains at a lower total cost than Roto-Rooter, even accounting for the brand premium. The fragmentation is defensive; it protects the small operator from national scale exactly as it protects Roto-Rooter from national competitors.
In hospice, the fragmentation is regulatory. The 1,900 operators in Los Angeles County persist not because they are efficient, but because they are grandfathered into a licensing regime that no longer issues new permits, or because they serve niche communities, religious, linguistic, ethnic, that VITAS cannot easily replicate. The fragmentation here represents a market segmentation that roll-ups cannot resolve. VITAS does not want these operators because they generate 6 percent margins, and they do not want to sell because they are lifestyle businesses or mission-driven nonprofits.
Chemed’s insight is that fragmentation is not a problem to be solved but a condition to be exploited. Roto-Rooter extracts premium pricing from the top 15 percent of the market that values speed and brand over cost. VITAS extracts premium margins from the subset of regulated markets that limit competition. Both businesses ignore the fragmented long tail because serving it would destroy returns. This is a strategy of elitism masquerading as mass market: focus on the profitable minority rather than the scale of the majority.
Yet this strategy leaves both businesses permanently incomplete. Roto-Rooter will never be a comprehensive home services provider; VITAS will never be a national hospice giant with 40 percent market share. They are designed to be niche players at scale, optimized for cash generation rather than market domination. The holding company structure allows this incompleteness to be a virtue rather than a flaw, because the cash they generate can be deployed elsewhere, nto the buyback program, into unrelated acquisitions, or into the bank account that awaits better opportunities.
The Diminishing Returns of Discipline
The bear case for Chemed is not that the businesses collapse, but that they settle. Roto-Rooter stabilizes at 3 percent revenue growth as the post-COVID normalization proves permanent and private equity competitors capture the bundled service market. VITAS stabilizes at 5 percent earnings growth as Medicare reimbursement tightens and the geographic expansion options dwindle. The corporate-level math then changes. With 6 percent earnings growth from operations and 2 percent share count reduction from buybacks, constrained by the dwindling float and rising stock price, the EPS CAGR falls to 8 percent.
Eight percent is not a disaster. It exceeds the market average. But it does not justify the premium valuation that Chemed currently commands, and it does not satisfy the expectations of a shareholder base accustomed to 21 percent. In this scenario, the capital-allocation discipline becomes a trap. The company has trained investors to expect shrinkage-fueled growth; when that growth slows, the multiple contracts. The buyback program, having retired 40 percent of the company, has exhausted its power just as the operational headwinds strengthen.
The alternative, abandoning the discipline to pursue operational growth, would be worse, validating the market’s skepticism and likely destroying value through ill-conceived diversification. Chemed is thus caught in a narrow corridor: continue the buybacks until the company disappears or is acquired, or pivot to growth and break the model. The historical evidence suggests that McNamara will choose the former, shrinking the company until it becomes too valuable to remain public. Whether his successor maintains that resolve will determine if Chemed remains an empire of care or becomes merely a well-managed plumbing and hospice company, indistinguishable from the fragmented competitors it has spent two decades outperforming.